SCTA01C
/ Sinocelltech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 27, 2022
A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19
(clinicaltrials.gov)
- P1/2 | N=0 | Withdrawn | Sponsor: Sinocelltech Ltd. | N=434 ➔ 0 | Not yet recruiting ➔ Withdrawn
Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 1
Of
1
Go to page
1